Evidence map›Paper›PMID 34249017›Full record

ArticleFrontiers in immunology2021

Case Report: Sars-CoV-2 Infection in a Vaccinated Individual: Evaluation of the Immunological Profile and Virus Transmission Risk.

Claudia Strafella, Valerio Caputo, Gisella Guerrera, Andrea Termine, Carlo Fabrizio, Raffaella Cascella, Mario Picozza, Carlo Caltagirone, Angelo Rossini, Maria Pia Balice and 4 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Claudia StrafellaGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, Rome, Italy.
Valerio CaputoGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, Rome, Italy.
Gisella GuerreraNeuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
Andrea TermineGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, Rome, Italy.
Carlo FabrizioGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, Rome, Italy.
Raffaella CascellaGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, Rome, Italy.
Mario PicozzaNeuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
Carlo CaltagironeDepartment of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy.
Angelo RossiniMedical Services, IRCCS Santa Lucia Foundation, Rome, Italy.
Maria Pia BaliceClinical Microbiology Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy.
Antonino SalviaMedical Services, IRCCS Santa Lucia Foundation, Rome, Italy.
Luca BattistiniNeuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
Giovanna BorsellinoNeuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
Emiliano GiardinaGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the COVID19 pandemic, a range of vaccines displayed high efficacy in preventing disease, severe outcomes of infection, and mortality. However, the immunological correlates of protection, the duration of immune response, the transmission risk over time from vaccinated individuals are currently under active investigation. In this brief report, we describe the case of a vaccinated Healthcare Professional infected with a variant of Sars-CoV-2, who has been extensively investigated in order to draw a complete trajectory of infection. The patient has been monitored for the whole length of infection, assessing the temporal viral load decay, the quantification of viral RNA and subgenomic mRNA, antibodies (anti Sars-CoV-2, IgA, IgG, IgM) and cell-mediated (cytokine, B- and T-cell profiles) responses. Overall, this brief report highlights the efficacy of vaccine in preventing COVID19 disease, accelerating the recovery from infection, reducing the transmission risk, although the use of precautionary measures against Sars-CoV-2 spreading still remain critical.

Indexed as

Health PersonnelAdultAsymptomatic DiseasesB-LymphocytesBNT162 VaccineBreakthrough InfectionsCOVID-19COVID-19 VaccinesDisease Transmission, InfectiousFemaleHumansImmunity, HumoralItalyRiskRNA, ViralSARS-CoV-2BNT162 VaccineCOVID-19 VaccinesRNA, ViralCOVID19immune responseimmunologySars-CoV-2 infectionvaccination

Identifiers

PMID34249017
PMCPMC8270685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.